Aytu BioPharma
As of the edition of 20 October 2026, Aytu BioPharma runs 6 drugs, 5 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Neos Therapeutics, Inc: acquired in 2021; successor Aytu Bioscience Inc
- Aytu Bioscience Inc: renamed in 2021
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methylphenidate | none listed | 11 |
| Rabeprazole | none listed | 1 |
| Zolpidem | none listed | 0 |
| Amphetamine | none listed | 2 |
| Carbinoxamine | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Aytu BioPharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 2 trials led